Skip to main
GHRS
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research PLC is advancing its clinical candidate GH001 through promising Phase IIb trial results, achieving a significant -15.5 placebo-adjusted improvement on the MADRS scale at Day 8, indicating strong antidepressant efficacy. The company's focus on novel mebufotenin therapies positions it favorably within a regulatory environment that is increasingly supportive of psychedelic treatments, potentially enhancing market opportunities in Europe and across other indications such as postpartum and bipolar depression. Positive data in concurrent studies underline the prospect of durable clinical improvements, contributing to a favorable long-term outlook for GH Research's financial performance and growth potential.

Bears say

GH Research PLC faces significant risks that contribute to a negative outlook on its stock, primarily due to the potential for unexpected safety events or efficacy challenges associated with its mebufotenin therapies. Limitations in clinical trial progress stemming from regulatory hurdles or requirements could lead to delays or even a halt in development, impacting the company's ability to successfully bring products to market and generate revenue. Furthermore, fluctuations in remission rates observed in studies raise concerns over the long-term effectiveness of its treatments, highlighting the uncertainty surrounding the company's future performance and profitability.

GHRS has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Strong Buy based on their latest research and market trends.

According to 9 analysts, GHRS has a Strong Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.